Cost-Effectiveness and Cost-Utility Analysis of ABVD Versus Beacopp in the Treatment of Advanced-Stage Hodgkin Lymphoma

Conclusions:The preferred treatment strategy for patients with newly diagnosed advanced-stage Hodgkin lymphoma is a BEACOPP regimen. This strategy maximizes life expectancy, quality-adjusted life years, and is the most cost-effective strategy, accounting for increased rates of hematologic toxicity, secondary malignancy, and infertility in patients receiving the BEACOPP strategy. The model was robust to sensitivity analyses of key variables tested through plausible ranges obtained from the published literature.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Tags: 902. Services Research-Malignant Diseases Poster I Source Type: research